Patents by Inventor Ligong Liu
Ligong Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109847Abstract: The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for inhibiting Class IIa versus Class I HDACs. The present application also relates to methods of using the compounds and to uses of the compounds, especially in relation to the prevention of a disease, disorder or condition associated with Class IIa HDAC activity. In one form, the compounds are (ortho-phenyl) phenyl hydroxamates. In another form, the compounds are as provided in Formula (I), wherein R1 is a phenyl or cycloalkenyl which may be optionally substituted.Type: ApplicationFiled: December 23, 2021Publication date: April 4, 2024Inventors: David FAIRLIE, Ligong LIU, Robert REID, Jeffrey MAK
-
Patent number: 10245262Abstract: The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.Type: GrantFiled: April 1, 2015Date of Patent: April 2, 2019Assignees: The University of Queensland, Monash University, The University of MelbourneInventors: Alexandra Jane Corbett, James McCluskey, Lars Kjer-Nielsen, Zhenjun Chen, Jamie Rossjohn, Onisha Patel, Richard William Birkinshaw, Sidonia Barbara Guiomar Eckle, David Paul Fairlie, Ligong Liu, Jeffrey Yam Wing Mak
-
Patent number: 10011602Abstract: The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.Type: GrantFiled: July 5, 2013Date of Patent: July 3, 2018Assignee: THE UNIVERSITY OF MELBOURNEInventors: Lars Kjer-Nielsen, James McCluskey, Alexandra Corbett, Jamie Rossjohn, Patel Onisha, David Paul Fairlie, Ligong Liu
-
Patent number: 9868763Abstract: The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.Type: GrantFiled: July 27, 2012Date of Patent: January 16, 2018Assignee: The University of QueenslandInventors: David Fairlie, Ligong Liu, Mei-Kwan Yau, Jacky Yung Suen, Robert Reid, Rink-Jan Lohman, Abishek Venkatasubramanian Iyer, Junxian Lim, Lindsay Charles Brown
-
Publication number: 20170209442Abstract: The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.Type: ApplicationFiled: April 1, 2015Publication date: July 27, 2017Inventors: Alexandra Jane Corbett, James McCluskey, Lars Kjer-Nielsen, Zhenjun Chen, Jamie Rossjohn, Onisha Patel, Richard William Birkinshaw, Sidonia Barbara Guiomar Eckle, David Paul Fairlie, Ligong Liu, Jeffrey Yam Wing Mak
-
Patent number: 9701711Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: GrantFiled: October 21, 2014Date of Patent: July 11, 2017Assignee: The University of QueenslandInventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
-
Publication number: 20150166542Abstract: The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.Type: ApplicationFiled: July 5, 2013Publication date: June 18, 2015Applicant: THE UNIVERSITY OF MELBOURNEInventors: Lars Kjer-Nielsen, James McCluskey, Alexandra Corbett, Jamie Rossjohn, Patel Onisha, David Paul Fairlie, Ligong Liu
-
Publication number: 20150065440Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.Type: ApplicationFiled: September 5, 2014Publication date: March 5, 2015Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond
-
Publication number: 20150038402Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: DAVID PAUL FAIRLIE, LIGONG LIU, MEI KWAN YAU, JACKY YUNG SUEN, ROBERT REID
-
Patent number: 8927503Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: GrantFiled: July 28, 2011Date of Patent: January 6, 2015Assignee: The University of QueenslandInventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
-
Patent number: 8901085Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: GrantFiled: July 28, 2011Date of Patent: December 2, 2014Assignee: The University of QueenslandInventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
-
Publication number: 20140315796Abstract: The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.Type: ApplicationFiled: July 27, 2012Publication date: October 23, 2014Applicant: The University of QueenslandInventors: David Fairlie, Ligong Liu, Mei-Kwan Yau, Jacky Yung Suen, Robert Reid, Rink-Jan Lohman, Abishek Venkatasubramania Iyer, Junxian Lim, Lindsay Charles Brown
-
Patent number: 8828952Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.Type: GrantFiled: October 16, 2008Date of Patent: September 9, 2014Assignee: Progen Pharmaceuticals LimitedInventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond
-
Publication number: 20130184226Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: ApplicationFiled: July 28, 2011Publication date: July 18, 2013Applicant: THE UNIVERSITY OF QUEENSLANDInventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen
-
Patent number: 8222381Abstract: New compounds and methods for the preparation of combinatorial libraries of potentially biologically active compounds are based on monosaccharides of formula I being a derivative of a furanose or pyranose form of a monosaccharide, .Type: GrantFiled: August 8, 2003Date of Patent: July 17, 2012Assignee: Alchemia LimitedInventors: Michael West, Peter Andrews, Tracie Elizabeth Ramsdale, Wim Meutermans, Giang Thanh Le, Chris Clark, Giovanni Abbenante, Ligong Liu
-
Patent number: 8173606Abstract: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.Type: GrantFiled: December 3, 2010Date of Patent: May 8, 2012Assignee: Progen Pharmaceuticals LimitedInventors: Vito Ferro, Jon Krueger Fairweather, Tomislav Karoli, Ligong Liu
-
Publication number: 20110130354Abstract: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.Type: ApplicationFiled: December 3, 2010Publication date: June 2, 2011Applicant: Progen Pharmaceuticals LimitedInventors: Vito Ferro, Jon Krueger Fairweather, Tomislav Karoli, Ligong Liu
-
Patent number: 7875592Abstract: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.Type: GrantFiled: March 4, 2005Date of Patent: January 25, 2011Assignee: Progen Pharmaceuticals LimitedInventors: Vito Ferro, Jon Krueger Fairweather, Tomislav Karoli, Ligong Liu
-
Publication number: 20070185037Abstract: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment, lowering of blood triglyceride levels and inhibition of cardiovascular disease of a mammalian subject.Type: ApplicationFiled: March 4, 2005Publication date: August 9, 2007Applicant: PROGEN INDUSTRIES LIMITEDInventors: Vito Ferro, Jon Fairweather, Tomislav Karoli, Ligong Liu
-
Patent number: RE46955Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.Type: GrantFiled: September 9, 2016Date of Patent: July 17, 2018Assignee: Progen PG500 Series Pty LtdInventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond